Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

B. Lowenberg, J. Beck, C. Graux, W van Putten, H.C. Schouten, L.F. Verdonck, A Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Dohner, A. Gratwohl, T. Pabst, G.J. OssenkoppeleJ. Maertens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2586-2591
JournalBlood
Volume115
Issue number13
DOIs
Publication statusPublished - 2010

Cite this

Lowenberg, B., Beck, J., Graux, C., van Putten, W., Schouten, H. C., Verdonck, L. F., ... Maertens, J. (2010). Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), 2586-2591. https://doi.org/10.1182/blood-2009-10-246470